Ardent Health, Inc. (NYSE:ARDT) Given Consensus Recommendation of “Hold” by Brokerages

Ardent Health, Inc. (NYSE:ARDT) has earned an average rating of “Hold” from the twelve brokerages that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $14.6667.

A number of analysts recently commented on ARDT shares. JPMorgan Chase & Co. lowered their price objective on Ardent Health from $15.00 to $12.00 and set a “neutral” rating for the company in a research report on Monday, November 24th. Weiss Ratings reiterated a “sell (d)” rating on shares of Ardent Health in a research report on Monday, December 29th. Guggenheim dropped their price target on shares of Ardent Health from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Leerink Partners set a $16.00 price objective on shares of Ardent Health in a report on Friday, November 14th. Finally, Wall Street Zen lowered shares of Ardent Health from a “buy” rating to a “hold” rating in a report on Sunday, November 23rd.

Ardent Health Price Performance

Shares of ARDT stock opened at $8.59 on Monday. The stock’s fifty day moving average is $9.18 and its 200-day moving average is $11.72. The stock has a market capitalization of $1.23 billion, a PE ratio of 5.92, a PEG ratio of 4.91 and a beta of 0.72. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.95 and a current ratio of 2.08. Ardent Health has a 52 week low of $8.28 and a 52 week high of $15.65.

Ardent Health (NYSE:ARDT) last announced its earnings results on Wednesday, November 12th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.10. The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.55 billion. Ardent Health had a net margin of 3.24% and a return on equity of 19.02%. Ardent Health has set its FY 2025 guidance at 0.850-1.030 EPS. Equities research analysts expect that Ardent Health will post 1.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Ardent Health

Several institutional investors have recently modified their holdings of ARDT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Ardent Health by 103.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,104 shares of the company’s stock valued at $194,000 after acquiring an additional 7,182 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Ardent Health by 1,684.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 767,862 shares of the company’s stock worth $10,558,000 after purchasing an additional 724,841 shares during the last quarter. Jane Street Group LLC increased its holdings in Ardent Health by 235.1% during the first quarter. Jane Street Group LLC now owns 57,468 shares of the company’s stock worth $790,000 after buying an additional 40,318 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Ardent Health by 574.9% during the 1st quarter. Acadian Asset Management LLC now owns 40,238 shares of the company’s stock worth $550,000 after purchasing an additional 34,276 shares during the last quarter. Finally, Strs Ohio bought a new stake in Ardent Health in the first quarter valued at approximately $494,000.

Key Stories Impacting Ardent Health

Here are the key news stories impacting Ardent Health this week:

• Negative Sentiment: Hagens Berman says a class action was filed after Ardent disclosed roughly $90M of adverse receivables/reserves adjustments that triggered a mid‑November ~33% share plunge; the firm seeks to represent investors harmed during the identified class period. Ardent Health (ARDT) Facing Securities Class Action Amid Receivables and Reserves Issues Driving 33% Plunge – Hagens Berman
• Negative Sentiment: Rosen Law Firm has announced a class action covering purchases between July 18, 2024 and November 12, 2025 and is urging investors to seek counsel — the lead‑plaintiff motion deadline is March 9, 2026, a date that can accelerate litigation activity. ROSEN, A RESPECTED AND LEADING FIRM, Encourages Ardent Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ARDT
• Negative Sentiment: Multiple other plaintiff firms (Glancy Prongay & Murray, Levi & Korsinsky, Bleichmar Fonti & Auld, Kirby McInerney, Faruqi & Faruqi, Pomerantz, Bragar Eagel & Squire and others) have filed notices or are soliciting lead‑plaintiff motions, increasing the likelihood of consolidated litigation and higher legal costs. Deadline Alert: Ardent Health, Inc. (ARDT) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
• Negative Sentiment: Several reminder notices (including from BFA Law, Portnoy, ClaimsFiler and others) emphasize the March 9 deadline for lead plaintiff appointments — such timelines typically accelerate discovery, media attention, and potential settlement pressure. ARDT CLASS REMINDER: Ardent Health, Inc. Class Action Deadline March 9 – Investors Notified to Contact BFA Law about its Filed Lawsuit to Protect Your Rights

Ardent Health Company Profile

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.